Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps

医学 慢性鼻-鼻窦炎 鼻息肉 皮肤病科 内科学
作者
Anju T. Peters,Joseph K. Han,Peter W. Hellings,Enrico Heffler,Philippe Gevaert,Claus Bachert,Yingxin Xu,Chien‐Chia Chuang,Binod Neupane,Jérôme Msihid,Leda P. Mannent,Patricia Guyot,Siddhesh Kamat
出处
期刊:The Journal of Allergy and Clinical Immunology: In Practice [Elsevier BV]
卷期号:9 (6): 2461-2471.e5 被引量:69
标识
DOI:10.1016/j.jaip.2021.01.031
摘要

Among patients with chronic rhinosinusitis with nasal polyps (CRSwNP), randomized clinical trials (RCTs) of biologics, such as anti-interleukin-4/interleukin-13 (dupilumab) and anti-immunoglobulin E (omalizumab), have demonstrated efficacy compared with intranasal corticosteroids (INCS). However, no head-to-head RCTs exist between biologics.To perform an indirect treatment comparison (ITC) of the efficacy of biologics plus INCS versus placebo (INCS) as a common comparator.Embase, MEDLINE, and Cochrane were searched for RCTs of biologics in CRSwNP. Bucher ITCs were performed for outcomes at week 24: nasal polyp score (NPS) (range, 0-8), nasal congestion (NC) (range, 0-3), loss of smell (range, 0-3), University of Pennsylvania Smell Identification Test (range, 0-40), total symptom score (range, 0-12), 22-item sinonasal outcome test (range, 0-110), and responder analyses based on NPS or NC improvement of 1 point or greater.Assessment of trial design, baseline characteristics, and outcome measures suggested that ITC was feasible with four phase 3 RCTs: dupilumab SINUS-24 and SINUS-52 (NCT02912468/NCT02898454) and omalizumab POLYP 1 and POLYP 2 (NCT03280550/NCT03280537). In the intent-to-treat population, dupilumab had significantly greater improvements from baseline to week 24 versus omalizumab across key outcomes: NPS (least squares mean difference [95% confidence interval], -1.04 [-1.63 to -0.44]), NC (-0.35 [-0.60 to -0.11]), loss of smell (-0.66 [-0.90 to -0.42]), University of Pennsylvania Smell Identification Test (6.70 [4.67-8.73]), and total symptom score (-1.18 [-1.95 to -0.41]). Improvement in the 22-item sinonasal outcome test was greater in dupilumab versus omalizumab but was not statistically significant. Dupilumab patients were significantly more likely to achieve ≥1-point improvement in NPS (odds ratio [95% CI] = 3.58 [1.82-7.04]) and NC (2.13 [1.12-4.04]) versus omalizumab.Although ITCs have limitations, these results demonstrated that dupilumab had consistently greater improvements in key CRSwNP outcomes versus omalizumab at week 24.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
学不懂数学应助茶茶采纳,获得20
1秒前
隐形曼青应助旧辞采纳,获得10
1秒前
何佳完成签到,获得积分10
2秒前
烟花应助coco采纳,获得10
2秒前
小晶完成签到,获得积分10
2秒前
zimablue完成签到,获得积分10
3秒前
慕青应助范先生采纳,获得10
3秒前
zzz完成签到,获得积分10
4秒前
5秒前
海盗船长完成签到,获得积分10
5秒前
等待寄云完成签到 ,获得积分10
5秒前
酷波er应助王冉冉采纳,获得10
6秒前
lcjynwe完成签到,获得积分10
7秒前
新奇完成签到 ,获得积分10
7秒前
Misty_发布了新的文献求助10
7秒前
iNk应助不会取名字采纳,获得20
7秒前
Orange应助Hannes采纳,获得10
7秒前
9秒前
多多少少忖测的情完成签到,获得积分10
9秒前
小马甲应助lx采纳,获得10
9秒前
10秒前
阔达冰兰发布了新的文献求助10
10秒前
GAO完成签到,获得积分10
10秒前
yy发布了新的文献求助10
11秒前
11秒前
11秒前
奋斗冬萱完成签到,获得积分10
11秒前
康园完成签到,获得积分10
12秒前
活泼的面包完成签到,获得积分10
14秒前
123456完成签到,获得积分10
15秒前
重要谷冬完成签到,获得积分10
15秒前
深情丸子发布了新的文献求助10
15秒前
15秒前
杰瑞完成签到,获得积分10
17秒前
17秒前
ding应助科研通管家采纳,获得10
18秒前
Akim应助科研通管家采纳,获得10
18秒前
领导范儿应助科研通管家采纳,获得10
18秒前
fang应助科研通管家采纳,获得10
18秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048